Abstract
The present industry update covers the period of September 2019, with information sourced primarily from company press releases, scientific literature and various news websites. This month saw several collaborations announced in the area of delivery of gene therapies, including collaborations betweenWize Pharma and Copernicus and REGENXBio and Clearside. Notable approvals by the FDA this month included Novo Nordisk's Oral Semaglutide and Insulet's Omnipod DASH system as an infusion pump for insulin delivery. Halozyme announced positive results from a Phase III trial evaluating fixed-dose subcutaneous combination of Genetech's Perjeta and Herceptin. Vascular Therapies announced that it had received positive initial data in Phase II/III trials using its proprietary sirolimus formulation, Sirogen, which employs a novel bio-resorbable collagen-based drug delivery.
| Original language | English |
|---|---|
| Pages (from-to) | 75-82 |
| Number of pages | 8 |
| Journal | Therapeutic Delivery |
| Volume | 11 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2020 |
Keywords
- competitor intelligence
- emerging technologies
- gene therapy
- partnering